Donepezil, an acetylcholinesterase (AChE) inhibitor, and memantine, an N-methyl-D-aspartate receptor (NMDAR; NR) antagonist, have been approved for the clinical treatment of AD. Here, ACHE is linked to Alzheimer disease.